MedTrace Logo

Randomized Controlled Trial of Subconjunctival Bevacizumab Injection in Impending Recurrent Pterygium

NCT01288404 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2011-02-02

No results posted yet for this study

Summary

Hypothesis: Subconjunctival bevacizumab injection may potentially suppress neovascularization in pterygium, preventing or retarding the progression of recurrence.

Conditions

  • Pterygium of the Conjunctiva and Cornea

Interventions

DRUG

Fluorometholone

topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks

DRUG

Bevacizumab

subconjunctival bevacizumab 1.25 mg/0.05mL

DRUG

Bevacizumab

subconjunctival bevacizumab 2.5 mg/0.1mL

DRUG

Bevacizumab

subconjunctival bevacizumab 3.75 mg/0.15mL

Sponsors & Collaborators

  • Ramathibodi Hospital

    lead OTHER

Principal Investigators

  • Kaevalin Lekhanont, MD · Ramathibodi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-09-30
Completion
2010-11-30

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01288404 on ClinicalTrials.gov